Alogliptin/metformin (Vipdomet®)
All Wales Medicines Strategy Group (AWMSG)
Record ID 32014001454
English
Authors' recommendations:
Alogliptin/metformin (Vipdomet®) is recommended as an option for restricted use for dual oral therapy within NHS Wales. Alogliptin/metformin (Vipdomet®) should be restricted for use in the following circumstances within its licensed indication for the treatment of adult patients aged 18 years and older with type 2 diabetes mellitus: • As an adjunct to diet and exercise to improve glycaemic control in adult patients, inadequately controlled on their maximal tolerated dose of metformin alone, or those already being treated with the combination of alogliptin and metformin as separate tablets. Alogliptin/metformin (Vipdomet®) is not recommended for use within NHS Wales outside of these circumstances.
Details
Project Status:
Completed
Year Published:
2014
URL for published report:
http://www.awmsg.org/awmsgonline/app/appraisalinfo/1271
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Wales, United Kingdom
MeSH Terms
- Humans
- Diabetes Mellitus, Type 2
- Drug Therapy, Combination
- Metformin
- Hypoglycemic Agents
- Uracil
- Piperidines
Contact
Organisation Name:
All Wales Medicines Strategy Group
Contact Address:
All Wales Therapeutics and Toxicology Centre, Academic Centre, University Hospital Llandough, Penlan Road, Penarth, Vale of Glamorgan CF64 2XX
Contact Name:
AWTTC@wales.nhs.uk
Contact Email:
AWTTC@wales.nhs.uk
Copyright:
AWTTC
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.